Epigral Q1FY26 results: profit drops 38% YoY

Key takeaway from the quarter

Epigral Limited reported a sharp year-on-year decline in profit for the quarter ended June 30, 2026 (Q1FY26), even as revenue grew at a healthy pace. Standalone net profit after tax (PAT) fell 38% YoY to ₹99.18 crore from ₹160.41 crore in Q1FY25. The company linked the decline largely to the absence of a one-time deferred tax credit booked in the base quarter, along with higher material costs. At the operating level, revenue from operations increased 16% to ₹705.36 crore from ₹606.54 crore. The company also stated that margin pressure continued due to increased cost of materials consumed.

What the company reported

On a standalone basis, Epigral’s PAT came in at ₹99.18 crore for Q1FY26. The corresponding consolidated PAT was ₹99.74 crore, compared with ₹160.69 crore in Q1FY25. Profit before tax (PBT) increased 25% to ₹133.18 crore from ₹106.73 crore. Despite higher PBT, the net profit line was hit by a higher tax expense in Q1FY26. The company’s basic earnings per share (EPS) declined in line with PAT.

Revenue growth but margin pressure

Revenue from operations rose to ₹705.36 crore, up from ₹606.54 crore a year earlier. The company attributed the increase to volume and price realisations in the Chloro Alkali segment. Even with the stronger top line, management flagged continued margin pressure from higher raw material costs. The results indicate that cost inflation and the tax base effect mattered more than growth in sales for reported profitability. The mix of volume and price helped revenue, but did not fully offset the cost headwinds.

The tax swing that changed reported profit

A key driver behind the YoY PAT decline was taxation. Epigral’s tax expense for Q1FY26 was ₹34.00 crore, versus a net tax credit of ₹53.68 crore in Q1FY25. The prior-year credit included a one-time deferred tax credit of ₹80.87 crore. This credit arose from remeasurement of deferred tax liabilities after the company opted for the reduced tax rate under Section 115BAA of the Income-tax Act, 1961. With that one-off benefit not repeating, the tax line reverted to an expense in Q1FY26.

Board approval and audit review

The Board of Directors approved the unaudited financial results on July 27, 2026. The disclosure was made pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditor M/s. S R B C & CO LLP issued a limited review report on the figures. The company also said the results were prepared in accordance with Ind AS 34 "Interim Financial Reporting" under Section 133 of the Companies Act, 2013. These references are standard for quarterly reporting but important for investors tracking compliance and review status.

Standalone snapshot: Q1FY26 vs Q1FY25

The quarter showed a divergence between operating profit before tax and net profit after tax, reflecting the tax base effect.

Stock move around the update

Trading data in the release showed Epigral’s share price at ₹1,103.00, with a decline of ₹27.45, or 2.43%. Another cited move showed ₹1,106.20, down ₹23.40, or 2.07%. While the exact timestamps were not specified, the figures indicate the stock was trading lower around the period when the update circulated. For investors, the immediate reaction often reflects how much of the profit decline was already priced in and how the market reads the non-recurring tax impact.

Corporate action: new subsidiary incorporated

Alongside the quarterly results, Epigral said it incorporated a new subsidiary for chemical manufacturing. The company did not provide additional details in the shared text such as the subsidiary’s name, location, or timeline for operations. Still, the move signals corporate structuring for manufacturing activities, which can be relevant for future capacity additions or project execution. Investors typically track such incorporations for clues on capex direction and segment expansion. Any financial impact will depend on scale and commissioning schedules that were not included here.

Why the results matter for investors

The quarter underlines the difference between underlying operating performance and reported profit driven by one-time tax items. Revenue growth of 16% and PBT growth of 25% suggest operational momentum, but PAT fell because the base quarter benefited from an unusually large tax credit. At the same time, the company flagged higher material costs, which can weigh on margins even when volumes and realisations improve. The reported numbers therefore present a mixed picture: stronger top line, cost pressure, and a tax-driven PAT swing.

Conclusion

Epigral’s Q1FY26 results show revenue growth to ₹705.36 crore, but PAT declined to ₹99.18 crore due to higher material costs and the absence of the prior-year deferred tax credit of ₹80.87 crore. The board approved the unaudited results on July 27, 2026, and the statutory auditor issued a limited review report. Investors will likely focus on how costs evolve and whether revenue strength in the Chloro Alkali segment sustains. Any further clarity on the newly incorporated chemical manufacturing subsidiary may also shape expectations in upcoming disclosures.